Clinic
Brooklyn Urgent Care PLLC
Brooklyn Urgent Care PLLC was paid $3.46M by Medicaid between Nov 2021 and Mar 2024, across 48 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 16% of everything it billed.
33Billing provider infoBROOKLYN URGENT CARE PLLC
BROOKLYN, NY 11203
BROOKLYN, NY 11203
33aNPI1063898096assigned 07/31/2015
33bProvider typeUrgent Care Clinic/Center
28Total paid$3.46M
24GClaims81,262
24DCodes billed48
24AFirst – last monthNov 2021 – Mar 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in New York
Rank by total paid#30 of 138
Median peer was paid$576K
This provider vs. median6.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 7,499 | $247K | |
| 2022 | 45,854 | $1.71M | |
| 2023 | 23,191 | $1.26M | |
| 2024incomplete | 4,718 | $240K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 16% | 4,409 | 4,256 | $553K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 14% | 15,265 | 13,351 | $473K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 4,904 | 4,649 | $421K |
| S9083 | Global fee urgent care centers | 11% | 4,264 | 3,691 | $397K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 6,608 | 6,101 | $364K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 10% | 6,697 | 6,641 | $346K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.8% | 3,147 | 3,131 | $269K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.9% | 1,988 | 1,600 | $136K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.9% | 5,432 | 4,703 | $135K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.8% | 5,083 | 5,022 | $132K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.3% | 2,016 | 1,615 | $46K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 3,379 | 2,526 | $37K |
36 more codes
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,220 | $20K |
| 0001A | <1% | 362 | $14K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 860 | $14K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,506 | $13K |
| 0124A | <1% | 258 | $10K | |
| 0002A | <1% | 227 | $9K | |
| 0134A | <1% | 189 | $7K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 61 | $7K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 46 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 203 | $5K |
| 0011A | <1% | 130 | $5K | |
| 0051A | <1% | 112 | $4K | |
| 90674 | <1% | 176 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,723 | $4K |
| 0052A | <1% | 92 | $4K | |
| 0071A | <1% | 78 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 13 | $3K |
| 90707 | <1% | 26 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 297 | $2K |
| 99051 | <1% | 4,236 | $2K | |
| 81000 | <1% | 1,181 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 33 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 13 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 35 | $1K |
| 81025 | <1% | 1,467 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 206 | $1K |
| 0004A | <1% | 21 | $838.49 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 34 | $774.78 |
| 93000 | <1% | 55 | $509.93 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 931 | $373.80 |
| 86580 | <1% | 56 | $215.05 | |
| 90686 | <1% | 61 | $55.54 | |
| 90611 | <1% | 17 | $14.70 | |
| 81002 | <1% | 106 | $11.27 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $0.56 |
| 90622 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEIFER, LAZER (OWNER)